Japan: The land that doesn't need Ozempic

Cultural and Social Norms

• Many argue Japan’s low obesity is primarily cultural: strong social norms, fat-shaming, and policies like “Metabo” waist checks and employer penalties create pressure to stay thin.
• Others are uncomfortable with government- or peer-enforced shame and see it as paternalistic or a “thought-police” risk, even if it works.
• Several note that norms around food, weight, and walking are deeply embedded from childhood in Japan and other East Asian countries.

Diet, Portions, and Processed Food

• Frequent contrast between Japanese/Korean smaller portions and US “supersized” meals and sides (e.g., fries, sugary drinks).
• Japan clearly has junk food, fried food, frozen convenience food, and sugary snacks, but they’re often eaten less frequently and in smaller quantities.
• Disagreement on villain: some point to “junk food” and ultra-processed foods; others emphasize sugar and sweet drinks specifically; others say overall calories (+25% in the US since the 1960s) matter most.
• US ingredients are seen as more heavily engineered (additives, HFCS, oils), though it’s unclear how much this explains obesity compared with quantity.

Walking, Urban Form, and Exercise

• Repeated theme: walkable, transit-oriented cities in Japan/Korea vs car-centric US suburbs. Just daily commuting/errands there can yield thousands of extra steps.
• Some argue walking’s calorie burn is small; others emphasize long-term cumulative effects, metabolic benefits, and appetite regulation.
• Consensus that diet dominates pure weight loss, but regular movement makes healthy eating easier and more sustainable.

Shame, Health, and Body Image

• Debate over “fat-shaming”: some see it as an effective population-level tool; others highlight mental-health harms, eating disorders, and doctor bias toward blaming weight for unrelated issues.
• Body-positivity is viewed by some as needed to counter decades of stigma; others think it downplays real health risks.

GLP‑1 Drugs (Ozempic, Wegovy, etc.)

• Some see widespread Ozempic use as symptom-treating instead of fixing food systems, culture, and urban design.
• Others stress obesity is not purely “willpower”; biology, inflammation, and appetite regulation matter, and some patients genuinely “need” GLP‑1 agonists.
• Concerns mentioned: cost, access (e.g., needing diabetes in Japan for a prescription), long-term side effects (thyroid, mood), and unclear net impact on healthcare spending.

Broader Causes and Open Questions

• Strong disagreement on root causes: lifestyle vs chemistry, environment vs personal responsibility.
• Multiple commenters caution that obesity trends are recent and multifactorial; the science is not “settled,” and simple narratives (sugar-only, walking-only, shame-only) seem incomplete.